KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase

European Journal of Pharmacology
Antonio Garrido MontalbanChristopher J Larson

Abstract

The tumor necrosis factor-alpha (TNF-alpha) cytokine, secreted by activated monocytes/macrophages and T lymphocytes, is implicated in several diseases, including rheumatoid arthritis, chronic obstructive pulmonary disease, inflammatory bowel disease, and osteoporosis. Monocyte/macrophage production of TNF-alpha is largely driven by p38alpha mitogen-activated protein kinase (MAP kinase), an intracellular soluble serine-threonine kinase. p38alpha MAP kinase is activated by growth factors, cellular stresses, and cytokines such as TNF-alpha and interleukin-l (IL-I). The primary contribution of p38alpha activation to excess TNF-alpha in settings of both chronic and acute inflammation has instigated efforts to find inhibitors of this enzyme as possible therapies for associated disease states. Analogue design, synthesis, and structure-activity studies led to the identification of 5-tert-butyl-N-cyclopropyl-2-methoxy-3-{2-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-2-oxo-acetylamino}-benzamide (KR-003048) as a potent inhibitor of the p38 MAP kinase signaling pathway in vitro and in vivo. The inhibition in vitro of human p38alpha enzyme activity and lipopolysaccharide (LPS)-induced p38 activation and subsequent TNF-alpha release is de...Continue Reading

References

May 12, 1994·Nature·J M KyriakisJ R Woodgett
Oct 4, 1996·The Journal of Biological Chemistry·J M Kyriakis, J Avruch
Apr 1, 1997·Nature Structural Biology·L TongC A Pargellis
Sep 28, 1999·Molecular Medicine Today·E Herlaar, Z Brown
Feb 17, 2000·Cellular Signalling·K Ono, J Han
Oct 29, 2000·Annals of the Rheumatic Diseases·R O WilliamsR N Maini
Jun 20, 2001·The Journal of Clinical Investigation·I K CampbellI P Wicks
Sep 21, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·M O HanniganC K Huang
Mar 16, 2002·Nature Structural Biology·Christopher PargellisJohn Regan
May 8, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Georg H WaetzigStefan Schreiber
Jun 8, 2002·Molecular and Cellular Biology·Alexey KotlyarovMatthias Gaestel
Jun 28, 2002·Journal of Medicinal Chemistry·John ReganCarol Torcellini
Nov 28, 2002·Biological Chemistry·Yu Shi, Matthias Gaestel
Dec 16, 2003·Arthritis and Rheumatism·Kurt RedlichJosef S Smolen
Jul 15, 2004·Current Opinion in Pharmacology·Jeremy Saklatvala
Sep 20, 2005·Bioorganic & Medicinal Chemistry Letters·Enrique L MichelottiMichael Karpusas
Sep 24, 2005·Current Topics in Medicinal Chemistry·David J DillerAxel Metzger
Sep 24, 2005·Current Topics in Medicinal Chemistry·John Hynes, Katerina Leftheri
Sep 24, 2005·Current Topics in Medicinal Chemistry·Swaminathan R Natarajan, James B Doherty
Mar 11, 2006·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Stefan SchreiberUNKNOWN BIRB 796 Study Group
Mar 8, 2008·Bioorganic & Medicinal Chemistry Letters·Antonio Garrido MontalbanChristopher J Larson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here